129 related articles for article (PubMed ID: 29997262)
1. Quantitative analysis of the mitochondrial proteome in human ovarian carcinomas.
Li N; Li H; Cao L; Zhan X
Endocr Relat Cancer; 2018 Oct; 25(10):909-931. PubMed ID: 29997262
[TBL] [Abstract][Full Text] [Related]
2. The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes.
Li N; Zhan X; Zhan X
Gynecol Oncol; 2018 Aug; 150(2):343-354. PubMed ID: 29921511
[TBL] [Abstract][Full Text] [Related]
3. Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis.
Zhan X; Li H; Qian S; Zhan X; Li N
J Vis Exp; 2019 Nov; (153):. PubMed ID: 31789316
[TBL] [Abstract][Full Text] [Related]
4. Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine.
Li N; Li H; Wang Y; Cao L; Zhan X
EPMA J; 2020 Dec; 11(4):661-694. PubMed ID: 33240452
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer circulating extracelluar vesicles promote coagulation and have a potential in diagnosis: an iTRAQ based proteomic analysis.
Zhang W; Peng P; Ou X; Shen K; Wu X
BMC Cancer; 2019 Nov; 19(1):1095. PubMed ID: 31718609
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer.
Chappell NP; Teng PN; Hood BL; Wang G; Darcy KM; Hamilton CA; Maxwell GL; Conrads TP
J Proteome Res; 2012 Sep; 11(9):4605-14. PubMed ID: 22900918
[TBL] [Abstract][Full Text] [Related]
7. Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique.
Huang Y; Zhang X; Jiang W; Wang Y; Jin H; Liu X; Xu C
Eur J Obstet Gynecol Reprod Biol; 2012 Nov; 165(1):96-103. PubMed ID: 22818854
[TBL] [Abstract][Full Text] [Related]
8. MASS SPECTROMETRY-BASED MITOCHONDRIAL PROTEOMICS IN HUMAN OVARIAN CANCERS.
Li N; Zhan X
Mass Spectrom Rev; 2020 Sep; 39(5-6):471-498. PubMed ID: 32020673
[TBL] [Abstract][Full Text] [Related]
9. Quantitative proteome analysis of ovarian cancer tissues using a iTRAQ approach.
Wang LN; Tong SW; Hu HD; Ye F; Li SL; Ren H; Zhang DZ; Xiang R; Yang YX
J Cell Biochem; 2012 Dec; 113(12):3762-72. PubMed ID: 22807371
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of the human ovarian carcinoma mitochondrial phosphoproteome.
Li N; Qian S; Li B; Zhan X
Aging (Albany NY); 2019 Aug; 11(16):6449-6468. PubMed ID: 31442208
[TBL] [Abstract][Full Text] [Related]
11. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
Haslene-Hox H; Oveland E; Woie K; Salvesen HB; Wiig H; Tenstad O
Biochim Biophys Acta; 2013 Nov; 1834(11):2347-59. PubMed ID: 23707566
[TBL] [Abstract][Full Text] [Related]
12. CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer.
Li T; Xue H; Guo Y; Guo K
Oncol Rep; 2014 Apr; 31(4):1825-31. PubMed ID: 24573179
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
14. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
[TBL] [Abstract][Full Text] [Related]
15. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
16. Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer.
Wu W; Wang Q; Yin F; Yang Z; Zhang W; Gabra H; Li L
Int J Oncol; 2016 Oct; 49(4):1651-65. PubMed ID: 27511453
[TBL] [Abstract][Full Text] [Related]
17. Quantitative proteomics reveals FLNC as a potential progression marker for the development of hepatocellular carcinoma.
Qi Y; Xu F; Chen L; Li Y; Xu Z; Zhang Y; Wei W; Su N; Zhang T; Fan F; Wang X; Qin X; Zhang L; Liu Y; Xu P
Oncotarget; 2016 Oct; 7(42):68242-68252. PubMed ID: 27626164
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
19. Understanding Ovarian Cancer: iTRAQ-Based Proteomics for Biomarker Discovery.
Swiatly A; Horala A; Matysiak J; Hajduk J; Nowak-Markwitz E; Kokot ZJ
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30065196
[TBL] [Abstract][Full Text] [Related]
20. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
